| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 05/31/2001 | WO2000071140A3 Methods and compositions for modulating immune response and for the treatment of inflammatory disease |
| 05/31/2001 | WO2000066098A3 Vitamin d derivatives for the treatment of systemic lupus erythematosus |
| 05/31/2001 | WO2000057864A3 Cyclic glycerophosphates and analogs thereof |
| 05/31/2001 | WO2000047194A9 METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR |
| 05/31/2001 | WO2000006712A3 Protein tyrosine phosphatase-1b (ptp-1b) deficient mice and uses thereof |
| 05/31/2001 | US20010002419 Homogeneous preparation of protein, e.g. leptin, modified at the N-terminal only by an anhydride, e.g. succinic anhydride, ethylenediaminetetraacetic dianhydride; improved solubility; no inflammation at injection sites |
| 05/31/2001 | US20010002398 (6S)- or 10 (6R,S)- tetrahydrofolic acid is crystallized in a polar medium with pH of 3.5 or greater and have a purity 98% |
| 05/31/2001 | US20010002397 24-Hydroxyvitamin D, analogs and uses thereof |
| 05/31/2001 | US20010002394 Use of a polypeptide containing specific amino acid sequence or analogue or derivatives as a drug for the treatment of diabetes together with an oral hypoglycemic agent |
| 05/31/2001 | DE19957156A1 New amino and fluoro substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocine derivatives useful in treatment of e.g. arrythmias, spasms, ischaemia, pain and neurodegenerative disorders |
| 05/31/2001 | DE19956848A1 Curcumin-Formulierungen Curcumin formulations |
| 05/31/2001 | CA2706113A1 Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| 05/31/2001 | CA2704975A1 Therapeutic intervention to mimic the effect of caloric restriction |
| 05/31/2001 | CA2395049A1 Pyrimidine derivatives as selective inhibitors of cox-2 |
| 05/31/2001 | CA2394803A1 Novel human protein kinases and protein kinase-like enzymes |
| 05/31/2001 | CA2392456A1 Assays and therapies for latent viral infection |
| 05/31/2001 | CA2392366A1 Major intrinsic protein (mip)-like polynucleotides, polypeptides, and antibodies |
| 05/31/2001 | CA2392327A1 Imidazo-pyridine derivatives as ligands for gaba receptors |
| 05/31/2001 | CA2392019A1 Method of forming a peptide-receptor complex with zsig33 |
| 05/31/2001 | CA2391986A1 Colloidal suspension of submicronic particles as vectors for active principles and method for preparing same |
| 05/31/2001 | CA2391526A1 A pharmaceutical composition for treatment of diseases associated with decrease in bone mass |
| 05/31/2001 | CA2391457A1 Phytosterol and phytostanol compositions |
| 05/31/2001 | CA2390923A1 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| 05/31/2001 | CA2387591A1 Use of indirubine derivatives for making medicines |
| 05/31/2001 | CA2386979A1 Periodontitis treating agent |
| 05/30/2001 | EP1103553A2 Substituted heterocyclic derivatives |
| 05/30/2001 | EP1103544A2 Piperidine derivatives and antiplatelet agents containing the same |
| 05/30/2001 | EP1103266A2 Formulations of curcumine |
| 05/30/2001 | EP1102855A1 Method for producing plants with increased flavonoid and phenolic compound content |
| 05/30/2001 | EP1102838A2 A method of modulating the efficiency of translation termination and degradation of aberrant mrna involving a surveillance complex comprising human upf1p, eucaryotic release factor 1 and eucaryotic release factor 3 |
| 05/30/2001 | EP1102762A2 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists |
| 05/30/2001 | EP1102757A1 Substituted oxazole and thiazole derivatives as hppar gamma and hppar alpha activators |
| 05/30/2001 | EP1102751A1 Novel bi- and tri-cyclic aza compounds and their uses |
| 05/30/2001 | EP1102750A1 Amide derivatives useful as inhibitors of the production of cytokines |
| 05/30/2001 | EP1102746A1 Substituted phenylamidines with antithrombotic action |
| 05/30/2001 | EP1102739A1 Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders |
| 05/30/2001 | EP1102595A2 Methods for increasing the solubility of nutritional materials using probiotic lactic acid-producing bacteria |
| 05/30/2001 | EP0689443B1 The use of bisphosphonates in bone surgery |
| 05/30/2001 | CN1297354A Dipeptide caspase inhibitors and use thereof |
| 05/30/2001 | CN1297353A Hypoylycemic agents |
| 05/30/2001 | CN1297350A Agents for relieving side effects |
| 05/30/2001 | CN1296830A Chinese-medicinal capsule for treating diabetes |
| 05/30/2001 | CN1066332C Hypoglycemic compound capsule |
| 05/29/2001 | US6239176 Administering to treat blood disorders like anemia; wound healing, anticarcinogenic and antiproliferative agents; genetic disorders |
| 05/29/2001 | US6239171 Tocotrienols and tocotrienol-like compounds and methods for their use |
| 05/29/2001 | US6239153 Insulin sensitivity enhancer with squaline synthesis inhibitor, which shows a potent depressive effect on diabetic hyperglycemia, |
| 05/29/2001 | US6239147 To treat cns, gastrointestinal and other disorders. substance p antagonists having improved activity and fewer side effects, treatment of emesis induced by antineoplastic agents, isochroman ring |
| 05/29/2001 | US6239138 Vitronectin receptor antagonist |
| 05/29/2001 | US6239135 Arylpiperazines having activity at the serotonin 1A receptor |
| 05/29/2001 | US6239114 Triterpene derivatives, antitumor |
| 05/29/2001 | US6239106 Family of protease inhibitors, and other biologic active substances |
| 05/29/2001 | US6239102 Concentrate comprising, as active agent, (3'-desoxy-3-oxo-mebmc)1-(val)2-cyclosporin, stabilizer selected from oleic acid or palmitoyl oleoyl phosphatidyl glycerol or salts thereof, ethanol |
| 05/29/2001 | US6238914 Nucleic acid |
| 05/29/2001 | US6238683 Drug delivery |
| 05/29/2001 | CA2195923C Azetidines |
| 05/25/2001 | WO2001036684A2 Mammalian toxicological response markers |
| 05/25/2001 | WO2001036610A1 Human enzymes of the metalloprotease family |
| 05/25/2001 | WO2001036605A2 2786, a human aminopeptidase |
| 05/25/2001 | WO2001036604A2 Nucleic acids encoding endotheliases, endotheliases and uses thereof |
| 05/25/2001 | WO2001036510A2 Use of poly(diallylamine) polymers |
| 05/25/2001 | WO2001036479A1 G-protein coupled receptor |
| 05/25/2001 | WO2001036454A1 Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
| 05/25/2001 | WO2001036450A1 S-allylmercaptoglutathione and uses thereof |
| 05/25/2001 | WO2001036425A2 Imidazole compounds used as phosphodiesterase vii inhibitors |
| 05/25/2001 | WO2001036416A1 Novel thiazolidinedione derivatives as antidiabetic agents |
| 05/25/2001 | WO2001036413A1 Aryloxy propanolamines for improving livestock production |
| 05/25/2001 | WO2001036412A1 Process for the preparation of aryloxy propanolamines |
| 05/25/2001 | WO2001036411A1 Crystalline salts of (s)-4-(3-[n-(2-[4-(5-carbamoyl-2-pyridyloxy)phenyl]-1,1-dimethylethyl)amino]-2-hydroxypropoxy)indole |
| 05/25/2001 | WO2001036403A1 Urea derivatives as anti-inflammatory agents |
| 05/25/2001 | WO2001036402A1 Novel 2-(n-cyanoimino)thiazolidin-4-one derivatives |
| 05/25/2001 | WO2001036401A1 Solid state forms of 5-[[6-[(2-fluorophenyl)methoxy]-2-naphthalenyl]methyl]-2,4-thiazolidinedione |
| 05/25/2001 | WO2001036398A1 Benzoxa- and benzthiazoles |
| 05/25/2001 | WO2001036390A1 Indazolyloxy propanolamines for improving livestock production |
| 05/25/2001 | WO2001036386A1 Diabetic remedy containing dipiperazine derivative |
| 05/25/2001 | WO2001036384A1 Polymorphic form of atorvastatin calcium |
| 05/25/2001 | WO2001036376A1 Novel phenylalanine derivatives |
| 05/25/2001 | WO2001035998A1 Compositions for transdermal and transmucosal administration of therapeutic agents |
| 05/25/2001 | WO2001035995A2 Tr3-specific binding agents and methods for their use |
| 05/25/2001 | WO2001035988A1 Use of glp-1 agonists for the inhibition of beta cell degeneration |
| 05/25/2001 | WO2001035986A2 Methods and compositions for modulating er-stress-induced cholesterol accumulation |
| 05/25/2001 | WO2001035984A1 Use of peptide |
| 05/25/2001 | WO2001035943A2 Dextrose and insulin fluid formulation for intravenous infusion |
| 05/25/2001 | WO2001035941A2 Novel composition based on a thiazolidinedione and metformin and use |
| 05/25/2001 | WO2001035940A2 Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride |
| 05/25/2001 | WO2001035933A2 A method of microencapsulation |
| 05/25/2001 | WO2001013905A3 Methods for the treatment of mental and vascular disorders |
| 05/25/2001 | WO2001000223A3 Multiple agent diabetes therapy |
| 05/25/2001 | WO2000078320A8 Cartilage enhancing food supplements and methods of preparing the same |
| 05/25/2001 | WO2000064426A3 Carnitine and inositol phosphate-containing composition useful as dietary supplement or drug |
| 05/25/2001 | CA2392090A1 G-protein coupled receptor |
| 05/25/2001 | CA2392076A1 Human enzymes of the metalloprotease family |
| 05/25/2001 | CA2391969A1 S-allylmercaptoglutathione and uses thereof |
| 05/25/2001 | CA2391913A1 Novel thiazolidinedione derivatives as antidiabetic agents |
| 05/25/2001 | CA2391875A1 Methods and compositions for modulating er-stress-induced cholesterol accumulation |
| 05/25/2001 | CA2391872A1 Use of peptides |
| 05/25/2001 | CA2391654A1 Aryloxy propanolamines for improving livestock production |
| 05/25/2001 | CA2391530A1 Tr3-specific binding agents and methods for their use |
| 05/25/2001 | CA2391429A1 Solid state forms of 5-¬¬6-¬(2-fluorophenyl)methoxy|-2-naphthalenyl|methyl|-2,4-thiazolidinedione |
| 05/25/2001 | CA2391087A1 Imidazole compounds as phosphodiesterase vii inhibitors |
| 05/25/2001 | CA2389289A1 Mammalian toxicological response markers |